Slide 1: Faster, more accurate gold analysis
Faster, more accurate gold analysis $75m Institutional Placement 7 November 2023 Dirk Treasure, Managing Director and CEO Brett Coventry, CFO
Slide 2: Important notice and disclaimers
Important notice and disclaimers Disclaimer The material in this presentation has been prepared by Chrysos Corporation Limited (ASX: C79) (“Chrysos” or the “Group") and is general background information about Chrysos’ current activities as at the date of this presentation. The information is given i
Slide 3: Positioned to capitalise on growth
Positioned to capitalise on growth Institutional Placement Highlights ✓ Strong pipeline of PhotonAssayTM deployments ✓ Landmark strategic partnership with Barrick Gold and MSALABS underpins sales momentum ✓ Barrick and MSALABS partnership validates PhotonAssayTM as a superior alternative to slower,
Slide 4: Year-to-date financial and operating highlights
Year-to-date financial and operating highlights Q1 FY24 Unaudited Total Revenue1 of $8.9m, reflecting 73% growth YoY $8.9m 1.0m Total Unaudited Revenue1 Samples Processed • MMAP Revenue of $7.7m, AAC Revenue of $1.1m • +37% growth YoY • +73% growth on YoY, +4% growth QoQ • +4% growth QoQ • +84% grow
Slide 5: FY24 Guidance
FY24 Guidance Forecastable revenue model provides reliable visibility FY24 Guidance: ■ FY24 Total Revenue range of $48m to $58m ■ Based on revenue from installed units and 18 units scheduled for deployment during FY24 ■ No provision for consumables supply (jars) ■ FY24 EBITDA range of $7m to $17m ■
Slide 6: Top line momentum continuing
Top line momentum continuing Secure committed revenue accounts for 87% of Q1 FY24 Unaudited Total Revenue Unaudited MMAP, AAC & Other Income ■ Minimum Monthly Assay Payments (MMAP) provide predictable and $10,000 +84% (MMAP +AAC only) sustainable minimum revenue $9,000 ■ Q1 FY24 MMAP was $7.7m, up 1
Slide 7: Executing on our global PhotonAssay roll out
Executing on our global PhotonAssayTM roll out Strong and sustainable growth underpinned by roll out of contracted units across the globe Existing PhotonAssayTM Reach TAM for PhotonAssayTM Units 700 610 Units 600 500 PhotonAssayTM Unit 410 On-site 400 Laboratories +561 Units Units 300 200 Off-site 1
Slide 8: Chrysos, Barrick and MSALABS partnership
Chrysos, Barrick and MSALABS partnership Global partnership for delivery of PhotonAssayTM to Barrick mine sites across four continents Chrysos Barrick Gold MSALABS Faster, more accurate + One of the world’s largest + Fast-growing international laboratory business gold analysis gold miners ■ Three in
Slide 9: Development PhotonAssay Gen II
Development PhotonAssayTM Gen II Building a sustainable and resilient business Supply chain Improved Deeper resilience + performance + integration ■ New generation of PhotonAssayTM units under development ■ Smaller unit footprint ■ Lighter, for ease of installation ■ Improved sample throughput ■ Sim
Slide 10: Use of Funds
Use of Funds Barrick’s global adoption of PhotonAssayTM is a watershed moment Balance Sheet Strengthening ■ $22m in undrawn debt ■ Improved balance sheet provides leverage to establish optimal debt structure Source and Use of Funds Sources Placement proceeds (before costs) $75m Existing cash on bala
Slide 11: Institutional Placement Details
Institutional Placement Details ▪ Single tranche non-underwritten institutional placement to sophisticated, professional and institutional investors to raise approximately $75 million (“Placement”) Offer Structure ▪ Approximately 11.4 million fully paid ordinary shares (“New Shares”) to be issued un
Slide 12: Institutional Placement Timetable
Institutional Placement Timetable Event Date Trading halt Monday, 6 November 2023 Placement Bookbuild conducted Monday, 6 November 2023 Trading halt lifted and announcement of completion of Placement Tuesday, 7 November 2023 Settlement of New Shares under the Placement Friday, 10 November 2023 Allot
Slide 13: In summary
In summary Chrysos to capitalise on growth ■ PhotonAssayTM has been deployed successfully across seven countries, three continents, and is supported by some of the world’s largest gold miners and laboratory companies ■ Barrick Gold and MSALABS partnership provides significant validation of PhotonAss
Slide 14: About Chrysos
CHRYSOS CORPORATION Assays at the speed of liaht About Chrysos
Slide 15: Chrysos – revolutionising the global mining industry
Chrysos – revolutionising the global mining industry Chrysos is a global provider of novel assay services through its proprietary PhotonAssayTM technology Disruptive Minerals Analysis Service and Lease Model with Industry Accepted Technology Technology Tier 1 Counterparties Displacing Traditional Fi
Slide 16: Our commercialisation journey
Our commercialisation journey The outcome of 20+ years of research and development Prototype Complete JORC and NI43-101 New Customer Announcements 1st PhotonAssayTM Max unit Companies cite PhotonAssayTM data Barrick Bulyanhulu in Tanzania contracts in market announcements MSALABS and PhotonAssayTM P
Slide 17: The Chrysos Vision
The Chrysos Vision To become the world’s leading provider of innovative assay services and technologies Market Challenge: Traditional assay techniques are slow, labour intensive, complex, destructive to the assay sample, and involve Fully-quantitative analysis in as little as 2 minutes! dangerously
Slide 18: PhotonAssay technology
PhotonAssayTM technology Best in class gold assaying with measurable benefits over traditionally used methods PhotonAssayTM vs. Traditional Fire Assay1 PhotonAssayTM value proposition Fire Assay PhotonAssayTM Faster turnaround Lower costs Simple to operate Results in as little as 2 minutes Time per
Slide 19: Delivering tangible benefits for miners
Delivering tangible benefits for miners PhotonAssayTM enables timely decision making and additional gold recovery The opportunity… PhotonAssayTM is embedded in the mining value chain PhotonAssayTM Value Add ■ Each year global miners are Exploration Fast turnaround for mine estimated to lose >$2.0 bi
Slide 20: An environmentally-friendly solution
An environmentally-friendly solution Substantially better for the environment and significantly safer than fire assay PhotonAssayTM has a substantial positive environmental impact that will continue to grow in tandem with the uptake of the technology ✓ PhotonAssayTM reduces CO2 emissions and elimina
Slide 21: High barriers to entry
High barriers to entry High barriers to entry supported by global IP rights Barriers to competitive entry Long-term leases with Protected by global guaranteed minimums, IP rights embedded at customer site 20+ years of R&D and Superior product to the investment in technology alternative Attractive va
Slide 22: Clear growth pathway
Clear growth pathway Clear organic growth plan with potential to expand TAM through additional commodities Business development pipeline ■ A growing global network of laboratory leases Growth Trajectory for Installed Units (cumulative) BMS Intertek ALS SGS AHK MSALABS ■ PhotonAssayTM unit commitment
Slide 23: Experienced leadership team
Experienced leadership team Supported by a well-respected and tenured board Senior leadership team Board of Directors Dirk Treasure Rob Adamson Kerry Gleeson Founding CEO & Managing Director Founder & Chair Independent Director • Metallurgist with a background in both • 20+ years’ experience in mini
Slide 24: Key Risks
Key Risks We recommend that potential investors read and consider the risks associated with Chrysos Corporation, its assets and the mining industry as set out in Chrysos’ most recent Annual Report and the Prospectus (and supplementary Prospectus) lodged in connection with its Initial Public Offering
Slide 25: Key Risks
Key Risks ■ Information technology failures or disruptions. The Group is dependent upon the use of computer, information and communications technology and systems. There is a risk that the Group’s technology systems could be interrupted or damaged by a diverse array of events, including natural disa
Slide 26: Key Risks
Key Risks ■ Counterparty risk. The Group faces various risks associated with engaging its various counterparties. This includes non-performance by the counterparty (e.g. technical or financial performance), concentration risk around the particular counterparty (e.g. exposure to individual customers,
Slide 27: Key Risks
Key Risks ■ Key personnel risk. The Group’s strategic development depends, in part, on the continued motivation and contributions of its senior management and Directors, who are experienced in the markets and business in which the Group operates. The Group’s future success will also depend on its ab
Slide 28: Foreign Selling Restrictions
Foreign Selling Restrictions International Offer Restrictions This document does not constitute an offer of new ordinary shares (“New Shares”) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may n
Slide 29: Foreign Selling Restrictions
Foreign Selling Restrictions European Union This document has not been, and will not be, registered with or approved by any securities regulator in the European Union. Accordingly, this document may not be made available, nor may the New Shares be offered for sale, in the European Union except in ci
Slide 30: Foreign Selling Restrictions
Foreign Selling Restrictions Singapore This document and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this document and any other document or materials in connec
Slide 31: Thank you
Thank you For more information, please visit chrysoscorp.com or contact us at investors@chrysoscorp.com